Guardion® Announces Statistically Significant Blood Assay Study Results
October 10 2019 - 10:30AM
Guardion Health Sciences, Inc. (“Guardion” or the “Company”)
(Nasdaq: GHSI) announced the formal results of a blood assay study
that established that Lumega-Z, Guardion’s proprietary medical food
designed specifically to replenish and restore the eye’s macular
protective pigment, provided 40 times higher concentrations and
bioavailability of mesozeaxanthin in the blood as compared to
over-the-counter AREDS2 gel cap supplements.
The study was conducted by Professor Richard A.
Bone, BSc, PhD, a member of the faculty of the Department of
Physics at Florida International University in Miami, Florida. Dr.
Bone is also a member of the Company’s Scientific Advisory Board.
Dr Bone was the first scientist to note the presence of
mesozeaxanthin in the macular protective pigment and to suggest its
importance in macular health. The study results are currently being
prepared for publication in late 2019.
David Evans, PhD, Guardion’s Chief Science
Officer, commenting on this large disparity in the blood
concentration levels resulting from the ingestion of Lumega-Z as
compared to AREDS2 gel cap supplements, stated, “Considerable
research demonstrates the importance of mesozeaxanthin for
protecting the macular region of the retina and staving off vision
loss due to macular degeneration. The results of this IRB-approved
clinical study clearly show the potent nature of our proprietary
formula and further explain the beneficial results observed and
documented in patients with eye disease receiving Lumega-Z.
About Guardion Health Sciences,
Inc.
Guardion® is an ocular health sciences company
that develops, formulates and distributes condition-specific
medical foods supported by evidence-based protocols, with an
initial medical food product that addresses a depleted macular
protective pigment, a known risk factor for age-related macular
degeneration (“AMD”), and a significant component of functional
vision performance. Guardion has also developed a proprietary
medical device, the MapcatSF®, which accurately measures the
macular pigment density, therefore providing the only two-pronged
evidence-based protocol for the treatment of a depleted macular
protective pigment.
About VectorVision®
VectorVision® specializes in the standardization
of contrast sensitivity, glare sensitivity, low contrast acuity,
and ETDRS acuity vision testing. Its patented standardization
system provides the practitioner or researcher the ability to
delineate very small changes in visual capability, either as
compared to the population or from visit to visit. VectorVision®’s
CSV-1000 device is considered the standard of care for clinical
trials. VectorVision® is a wholly-owned subsidiary of Guardion.
Guardion has completed development of the
proprietary VectorVision® CSV-2000 standardized contrast
sensitivity test and recently introduced the commercial product to
the marketplace. The CSV-2000 is the only computer-generated vision
testing instrument available that will provide the optical
marketplace with the Company’s proprietary, industry-standard
contrast sensitivity test, along with a full suite of standard
vision testing protocols. The proprietary standardization
methodology incorporated into the CSV-2000 includes a patented
technology known as AcQviz that automatically and constantly
measures and adjusts screen luminance to a fixed standard light
level for vision testing.
Forward-Looking Statement
Disclaimer
Certain statements in this press release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements
involve unknown risks and uncertainties that may individually or
materially impact the matters discussed herein for a variety of
reasons that are outside the control of the Company, including, but
not limited to, the Company’s ability to raise sufficient financing
to implement its business plan and its ability to successfully
develop and commercialize its proprietary products and
technologies. Readers are cautioned not to place undue reliance on
these forward-looking statements, as actual results could differ
materially from those described in the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company’s under the caption “Risk Factors” in the
Company’s’ Annual Report on Form 10-K for the year ended December
31, 2018 and the Company’s other filings made with SEC, which are
available at the SEC’s website (www.sec.gov). Forward-looking
statements included herein are made as of the date hereof, and the
Company does not undertake any obligation to update publicly such
statements to reflect subsequent events or circumstances.
Investor Relations Contact: Michael Porter
Porter, LeVay & Rose Telephone: (212) 564-4700 E-mail:
matthew@plrinvest.com
Guardion Health Sciences, Inc.15150 Avenue of
Science, Ste. 200 San Diego, CA 92128Ph 858.605.9055; Fax
858.630.5543www.guardionhealth.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Sep 2023 to Sep 2024